DAVID M. NATHAN, M.D.; LLOYD AXELROD, M.D.; JEFFREY S. FLIER, M.D.; DANIEL B. CARR, M.D.
Three patients with antibody-mediated insulin resistance were treated with U-500 regular insulin subcutaneously. Insulin requirements decreased dramatically (55% to 75%) when therapy was changed from U-100 NPH pork to equivalent doses of U-500 regular pork insulin. There was no difference in antibody affinity for the insulin in these two preparations as shown by competition experiments. These observations demonstrate that U-500 insulin is a useful alternative in the treatment of antibody-mediated insulin resistance. The mechanism for this effect is yet to be determined.
DAVID M. NATHAN, LLOYD AXELROD, JEFFREY S. FLIER, DANIEL B. CARR. U-500 Insulin in the Treatment of Antibody-Mediated Insulin Resistance. Ann Intern Med. 1981;94:653–656. doi: 10.7326/0003-4819-94-5-653
Download citation file:
Published: Ann Intern Med. 1981;94(5):653-656.
Cardiology, Coronary Risk Factors, Diabetes, Endocrine and Metabolism.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use